📇 Rhumatologue ·

MME MARIE-JOSE MICHEL

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
45 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10001932846

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Annals of the rheumatic diseases · 2008

📚 296 citations🎯 RCR 8.02Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases

Blood · 2009

📚 194 citations🎯 RCR 5.51Top 7% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Evans syndrome (ES) is a rare disease characterized by the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and/or immune neutropenia. To better describe the characteristics and outcome of ES in adults, a survey was initiated in 2005. The data from 68 patients (60% of them women) fulfilling strict inclusion criteria for ES are reported. The mean age at time of ITP and/or AIHA onset was 52 plus or minus 33 years, both cytopenias occurred simultaneously in 37 cases (54.5%). ES was considered as “primary” in 34 patients (50%) but was associated with an underlying disorder in half of the cases, including mainly systemic lupus, lymphoproliferative disorders, and common variable immunodeficiency. All patients were given corticosteroids, but 50 of them (73%) required at least one “second-line” treatment, including splenectomy(n = 19) and rituximab (n = 11). At time of analysis, after a mean follow-up of 4.8 years, only 22 patients (32%) were in remission off treatment; 16 (24%) had died. In elderly patients, the risk of cardiovascular manifestations related to AIHA seems to be higher than the ITP-related risk of severe bleeding. In conclusion, ES is a potentially life-threatening condition that may be associated with other underlying autoimmune or lymphoproliferative disorders.

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease

The Journal of rheumatology · 2003

📚 166 citations🎯 RCR 4.70Top 9% NIH

Cookies & analyse de trafic

MME MARIE-JOSE MICHEL

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (1)

Top publications · les plus citées

Publications scientifiques (45) — classées par pathologie

Transversal15

Lupus8

Biothérapies non-anti-TNF4

SAPL4

Connectivite mixte3

Anti-TNF2

csDMARDs2

Revue générale2

Anti-IL-231

Arthrite juvénile1

Case report / série1

Économie santé1

Épidémiologie & registres1

Ostéoporose1

Pédiatrie1

Pharmacovigilance1

Revue / méta-analyse1

Sclérodermie1

Vascularites1

Partager cette fiche